Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
In February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla®) received regulatory approval in the United States for treatment-refractory human epidermal growth factor receptor 2 (HER2) positive metastatic or locally advanced breast cancer based on results from EMILIA, a large phase III trial that co...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2014-09-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/1758834014539183 |
| _version_ | 1828428869666865152 |
|---|---|
| author | Parvin F. Peddi Sara A. Hurvitz |
| author_facet | Parvin F. Peddi Sara A. Hurvitz |
| author_sort | Parvin F. Peddi |
| collection | DOAJ |
| description | In February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla®) received regulatory approval in the United States for treatment-refractory human epidermal growth factor receptor 2 (HER2) positive metastatic or locally advanced breast cancer based on results from EMILIA, a large phase III trial that compared standard of care lapatinib plus capecitabine to T-DM1. Several other studies have been reported in the metastatic setting and multiple trials are ongoing or planned in the neoadjuvant, adjuvant and advanced disease settings. Here we provide an updated and comprehensive review of clinical trials evaluating T-DM1, discuss management of toxicity associated with this drug, propose potential mechanisms of resistance and offer practical considerations for the treating oncologist. |
| first_indexed | 2024-12-10T17:24:11Z |
| format | Article |
| id | doaj.art-22ac18e7a89d4d729001531a9f00b68f |
| institution | Directory Open Access Journal |
| issn | 1758-8340 1758-8359 |
| language | English |
| last_indexed | 2024-12-10T17:24:11Z |
| publishDate | 2014-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-22ac18e7a89d4d729001531a9f00b68f2022-12-22T01:39:53ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83401758-83592014-09-01610.1177/1758834014539183Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potentialParvin F. PeddiSara A. HurvitzIn February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla®) received regulatory approval in the United States for treatment-refractory human epidermal growth factor receptor 2 (HER2) positive metastatic or locally advanced breast cancer based on results from EMILIA, a large phase III trial that compared standard of care lapatinib plus capecitabine to T-DM1. Several other studies have been reported in the metastatic setting and multiple trials are ongoing or planned in the neoadjuvant, adjuvant and advanced disease settings. Here we provide an updated and comprehensive review of clinical trials evaluating T-DM1, discuss management of toxicity associated with this drug, propose potential mechanisms of resistance and offer practical considerations for the treating oncologist.https://doi.org/10.1177/1758834014539183 |
| spellingShingle | Parvin F. Peddi Sara A. Hurvitz Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential Therapeutic Advances in Medical Oncology |
| title | Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential |
| title_full | Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential |
| title_fullStr | Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential |
| title_full_unstemmed | Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential |
| title_short | Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential |
| title_sort | ado trastuzumab emtansine t dm1 in human epidermal growth factor receptor 2 her2 positive metastatic breast cancer latest evidence and clinical potential |
| url | https://doi.org/10.1177/1758834014539183 |
| work_keys_str_mv | AT parvinfpeddi adotrastuzumabemtansinetdm1inhumanepidermalgrowthfactorreceptor2her2positivemetastaticbreastcancerlatestevidenceandclinicalpotential AT saraahurvitz adotrastuzumabemtansinetdm1inhumanepidermalgrowthfactorreceptor2her2positivemetastaticbreastcancerlatestevidenceandclinicalpotential |